2-甲基己腈 | 20654-42-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-甲基己腈
• 英文名称: 2-methylhexanenitrile
• 英文别名: 2-Butyl-propionitril；2-methylhexanonitrile；2-Methyl-hexannitril；2-cyanohexane
• CAS: 20654-42-6
• 化学式: C₇H₁₃N
• 分子量: 111.187
• InChiKey: PZYFAYMXLISRGL-UHFFFAOYSA-N

物化性质

• 保留指数：
  913

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-甲基己腈 在 硫酸 作用下， 生成 2-甲基己酰胺
  参考文献：
  名称：

  A Study of the Alkylation of 2-Phenylbutanenitrile with Butyl Chlorides¹

  摘要：

  DOI：

  10.1021/jo01103a030
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氢氧化钾 作用下， 生成 2-甲基己腈
  参考文献：
  名称：

  de Hoffmann; Barbier, Bulletin des Societes Chimiques Belges, 1936, vol. 45, p. 570

  摘要：

  DOI：

文献信息

• Studies on Nitrile Salts. I. Dimerization of Nitriles Having α-Hydrogen in the Presence of Hydrogen Chloride
  作者：Shozo Yanagida、Tetsuo Fujita、Masataka Ohoka、Ichiro Katagiri、Saburo Komori

  DOI：10.1246/bcsj.46.292

  日期：1973.1

  chloroacetonitrile was confirmed to be N-(α,α,β-trichloroethyl)chloroacetamidine hydrochloride. The scope and limitations of the dimerization reaction of nitriles having α-hydrogen with HCl were studied. Most nitriles having α-hydrogen react with HCl to give N-(α-chloroalkenyl)alkylamidine hydrochlorides (3). Their hydrolysis to diacylamines (4) was also investigated.

  重新研究了先前报道的几种稳定腈-HCl 盐的组成和结构。它们中的大多数已被发现具有 2RC≡N·2HCl 的组成，并已通过质量和 NMR 光谱分析确定为 N-(α-氯烯基) 烷基脒盐酸盐 (3)。然而，来自氯乙腈的 2:3 加合物被证实为 N-(α,α,β-三氯乙基) 氯乙脒盐酸盐。研究了含α-氢的腈与HCl的二聚反应的范围和局限性。大多数含有 α-氢的腈与 HCl 反应生成 N-(α-氯烯基) 烷基脒盐酸盐 (3)。还研究了它们水解成二酰胺 (4)。
• [EN] PYRIMIDINE AND PYRIDINE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF<br/>[FR] DÉRIVÉS DE PYRIMIDINE ET DE PYRIDINE ET LEUR UTILISATION POUR TRAITER OU PRÉVENIR LA GRIPPE, OU POUR ATTÉNUER SES SYMPTÔMES
  申请人：SAVIRA PHARMACEUTICALS GMBH

  公开号：WO2017133667A1

  公开（公告）日：2017-08-10

  Provided herein is a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing influenza.

  本文提供的是一种化合物，其化学式为（I），可以是药用盐、溶剂合物、多型体、前药、共药、共晶、互变异构体、消旋体、对映体或二对映体，或它们的混合物形式，该化合物在治疗、改善或预防流感方面具有用处。
• Efficient nickel-catalyzed hydrocyanation of alkenes using acetone cyanohydrin as a safer cyano source
  作者：Koji Nemoto、Tsuyoshi Nagafuchi、Ken-ichi Tominaga、Kazuhiko Sato

  DOI：10.1016/j.tetlet.2016.06.036

  日期：2016.7

  nickel catalyst prepared in situ from a Ni(II) compound, phosphine ligand, and zinc powder was found to be an efficient catalyst system for the hydrocyanation of various alkenes using acetone cyanohydrin as a safer cyano source. The combination of NiCl2·6H2O and 1,3-bis(diphenylphosphino)propane was the most efficient catalyst precursor in DMF. Under the optimized conditions, various styrenes, heterocyclic

  发现由Ni（II）化合物，膦配体和锌粉原位制备的活性镍催化剂是使用丙酮氰醇作为较安全的氰基源对各种烯烃进行氢氰化的有效催化剂体系。NiCl 2 ·6H 2 O和1,3-双（二苯基膦基）丙烷的组合是DMF中最有效的催化剂前体。在优化的条件下，各种苯乙烯，杂环烯和脂族烯烃以优异的收率转化为相应的腈。
• Method for producing organic compounds by substituting halogen atoms
  申请人：MITSUI CHEMICALS, INC.

  公开号：EP1486479A1

  公开（公告）日：2004-12-15

  The invention pertains to a method in which a halogen atom of an organic compound is replaced with a group derived from a nucleophilic agent, at high yield and high efficiency, by the following method which includes a step of reacting the nucleophilic agent with an organic material having a halogen atom bonded to a carbon atom having four σ bonds, more specifically: a method for producing an organic compound having Q, the method including a step of reacting a compound represented by general formula (2) with an organic starting material having at least one halogen atom bonded to a carbon atom having four σ bonds so as to replace the halogen atom in the organic starting material with Q:         MQa     (2) (wherein M represents an alkali metal atom, an alkali earth metal atom, or a rare earth metal atom; Q represents a moiety of an inorganic acid or an active hydrogen compound derived by eliminating a proton, wherein Q is a halogen atom different from the halogen atom in the organic starting material having the halogen atom bonded to the carbon atom having the four σ bonds; and a represents an integer of 1 to 3) in the presence of a compound represented by general formula (1) (wherein Z- represents an anion derived by eliminating a proton from an inorganic acid or an active hydrogen compound; R2 is the same or different; R2 each independently represent a C1-C10 hydrocarbon group or two R2 on the same nitrogen atom may be bonded with each other to form a ring with the nitrogen atom).

  这项发明涉及一种方法，其中有机化合物中的卤素原子被来自亲核试剂的基团取代，且产率高效率高，通过以下方法实现，包括以下步骤：将亲核试剂与具有与碳原子形成四个σ键的卤素原子相结合的有机材料反应的步骤，更具体地说：一种用于生产具有Q的有机化合物的方法，包括以下步骤：将由通式（2）表示的化合物与至少一个卤素原子与碳原子形成四个σ键的有机起始材料反应，以将有机起始材料中的卤素原子替换为Q：         MQa     (2) （其中M代表碱金属原子、碱土金属原子或稀土金属原子；Q代表由消除质子衍生的无机酸或活性氢化合物的基团，其中Q是不同于有机起始材料中卤素原子的卤素原子，该卤素原子与具有四个σ键的碳原子相结合；a表示1到3的整数），在通式（1）表示的化合物的存在下 （其中Z-代表由无机酸或活性氢化合物中消除质子衍生的阴离子；R2相同或不同；R2各自独立地表示C1-C10烃基，或者两个R2在同一氮原子上可能与彼此结合形成与氮原子的环）。
• [EN] INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF<br/>[FR] DÉRIVÉS D'INDAZOLYL-SPIRO [2,3] HEXANE-CARBONITRILE COMME INHIBITEURS DE LRRK2, COMPOSITIONS PHARMACEUTIQUES, ET UTILISATIONS DE CEUX-CI
  申请人：MERCK SHARP & DOHME

  公开号：WO2019074810A1

  公开（公告）日：2019-04-18

  The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1A, R1B, X, Y, RZ and R2 are as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

  本发明涉及Formula (I)的某些取代的反向吲唑化合物及其药学上可接受的盐，其中R1A、R1B、X、Y、RZ和R2如本文所定义，这些化合物是LRRK2激酶的强效抑制剂，并且在治疗或预防LRRK2激酶参与的疾病，如帕金森病和本文所述的其他疾病和疾病中有用。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗LRRK-2激酶参与的这类疾病中使用这些化合物和组合物。